No Data
No Data
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
How Much Upside Is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $75
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?
Ionis Pharmaceuticals Management to Meet With Oppenheimer
Strong Week for Ionis Pharmaceuticals (NASDAQ:IONS) Shareholders Doesn't Alleviate Pain of Five-year Loss
Unlock the Full List
守株待鹅 : Goddess, which one are you Bullish on?